Monoclonal anti-A antibody removal by synthetic A antigen immobilized on specific antibody filters.
Removal of blood group anti-A and anti-B antibodies can prevent hyperacute organ rejection in ABO-incompatible transplantation. We are developing an extracorporeal-specific antibody filter (SAF) as an immunoadsorption device for direct removal of ABO blood group antibodies from whole blood, without the need for plasma separation and plasma exchange. A hollow fiber-based small scale SAF (mini-SAF) device was fabricated and synthetic A antigen, Atrisaccharide (Atri) conjugated to activated polyacrylic acid, was immobilized on the fiber lumen surface. Monoclonal antibody anti-A IgM were specifically removed up to 70% of initial antibodies using mini-SAF device. The monoclonal anti-A capture experiments on mini-SAF indicated that antibody removal relative to the initial concentration is independent of inlet concentration in the beginning; however, as the surface starts saturating with bound antibodies, removal becomes dependent on inlet concentration. No significant effect of flow rate on removal rate was observed. The radial diffusion and axial convection-based mathematical model developed for unsteady state antibody removal was in good agreement with the experimental data and showed that the antibody removal rate can be maximized by increasing the antibody-binding capacity of the SAF.
Gautam
Shalini
S
McGowan Institute for Regenerative Medicine, University of Pittsburgh, 215 McGowan Institute, 3025 East Carson Street, Pittsburgh, Pennsylvania 15203, USA.
Korchagina
Elena Y
EY
Bovin
Nicolai V
NV
Federspiel
William J
WJ
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification*; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification*; D020099:Coated Materials, Biocompatible / Q000737:chemistry*; D004867:Equipment Design; D019544:Equipment Failure Analysis; D005112:Extracorporeal Circulation / Q000295:instrumentation* / Q000379:methods; D008070:Lipopolysaccharides / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification*; D008567:Membranes, Artificial; D011485:Protein Binding; D014462:Ultrafiltration / Q000295:instrumentation* / Q000379:methods
C055610:A antigen (Brucella abortus); D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D020099:Coated Materials, Biocompatible; D008070:Lipopolysaccharides; D008567:Membranes, Artificial